Clinical Trial Update: BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

View source ↗

Summary

An update on the BRM421 ophthalmic solution being studied for Limbal Stem Cell Deficiency, including the current status of the clinical trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limbal Stem Cell Deficiency

Drugs mentioned

• BRM421 Ophthalmic Solution (BRM421)

Snippet

Sponsor: BRIM Biotechnology Inc. | Conditions: Limbal Stem Cell Deficiency (LSCD) | Status: AVAILABLE